Sophie C. Kunte

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

PSMA expression assessed by [18F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide.

PSMA expression assessed by [18F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: August 15, 2025

Options in nuclear medicine for advanced prostate cancer in practice

Options in nuclear medicine for advanced prostate cancer in practice

Journal: Urologie (Heidelberg, Germany)

Published: July 06, 2025

Quantitative [18F]FDOPA PET/CT for the characterization of biochemical phenotypes in paraganglioma and pheochromocytoma.

Quantitative [18F]FDOPA PET/CT for the characterization of biochemical phenotypes in paraganglioma and pheochromocytoma.

Journal: EJNMMI reports

Published: July 03, 2025

Assessment of continuous glucose monitoring (CGM) in type 2 diabetes: What should the general practitioner know?

Assessment of continuous glucose monitoring (CGM) in type 2 diabetes: What should the general practitioner know?

Journal: MMW Fortschritte der Medizin

Published: June 04, 2025

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma.

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma.

Journal: Molecular imaging and biology

Published: June 02, 2025

FAP-Directed Imaging and Therapy in Head and Neck Cancer of Unknown Primary.

FAP-Directed Imaging and Therapy in Head and Neck Cancer of Unknown Primary.

Journal: Cancers

Published: May 30, 2025

Feasibility of different meningioma delineation approaches on [18F]SiTATE PET/CT imaging.

Feasibility of different meningioma delineation approaches on [18F]SiTATE PET/CT imaging.

Journal: Discover oncology

Published: April 27, 2025

Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma.

Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma.

Journal: Cancers

Published: April 22, 2025

[99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer.

[99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 13, 2025

Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals.

Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals.

Journal: Cancers

Published: January 30, 2025

Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.

Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 27, 2024

Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders.

Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 16, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026